Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.
Read Full NewsHome visits — once common and now resurging — flip the dynamic, as the clinician becomes a guest in the patient's home. Experts say as both learn more about each other than is possible in-office, trust can build.
Higher body fat percentage, rather than BMI, is associated with reduced sperm count and disrupted reproductive hormone levels in men.
Standard TKI doses are often too high for long-term care. Dr Mark Kris shares his strategy for smart dose reductions that protect patient outcomes.
Cure rates are climbing, and so is the complexity of getting there. Dr Yara Abdou takes a closer look at optimizing HER2+ early-stage breast cancer therapy.
Direct primary care is more than medicine. Dr Rajdeep Dhami shares what physicians should know before starting DPC, from operations and branding to boundaries and community.
1.
What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?
2.
Citing a cancer risk, the EPA sets a new limit on medical sterilization chemicals.
3.
Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.
4.
Specific suicidal patterns mark the highest risk.
5.
Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors
1.
Unlocking the Power of Cryoprecipitate: A Comprehensive Guide
2.
Precision Era in Pediatric Oncology, from Genomic Breakthroughs to Lifelong Learning
3.
Fc Receptor Mediated Pharmacology of Therapeutic Antibodies
4.
Sorafenib: Understanding the science behind a powerful cancer drug
5.
Unveiling Canine Blood Clots Over Time: A Look at Low-Field MRI's Diagnostic Potential
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
5.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge